USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: RXGEN, INC.
Address: 100 DEEPWOOD DRIVE
HAMDEN, CT 06517-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,606,782.00 5
SBIR Phase II $2,488,478.00 2

Award List:

Toxicogenomics of Hepatotoxicity in Monkeys

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Matthew S. Lawrence
Award Amount: $249,123.00
Abstract:
DESCRIPTION (provided by applicant): SBIR Phase I Research: This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical… More

Genomic markers of environmental toxins for Parkinsonism

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Matthew S. Lawrence
Award Amount: $227,763.00
Abstract:
DESCRIPTION (provided by applicant): Parkinson's disease is a prevalent and devastating neurodegenerative condition of unknown etiology. One prominent hypothesis holds that the selective loss of the nigrostriatal dopaminergic neurons characteristic of the disease results from damage from… More

Toxicogenomics of Hepatotoxicity in Monkeys

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Matthew S. Lawrence
Award Amount: $1,126,036.00
Abstract:
DESCRIPTION (provided by applicant): SBIR Phase I Research: This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical… More

Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven R. Gullans
Award Amount: $208,554.00
Abstract:
DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CMS), and a considerable hurdle to the delivery of therapeutic agents. A technology allowing safe, targeted,… More

Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,362,442.00
Abstract:
DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CNS), as well as a considerable hurdle to the delivery of therapeu tic agents. A technology allowing safe,… More

Silencing cardiac-specific microRNAs to prevent pathological remodeling in conges

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Matthew S. Lawrence – 203-498-9706
Award Amount: $718,304.00
Abstract:
DESCRIPTION (provided by applicant): Heart disease remains the primary cause of morbidity and mortality in the industrialized world and continues to incur costs estimated at 30 billion per year, despite detailed understanding of the mechanisms governing cardiac function and contractility. MicroRNAs… More

Self-advocacy training for students with cochlear implants entering college

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Matthew S. Lawrence – 203-498-9706
Award Amount: $203,038.00
Abstract:
Optic nerve and retinal diseases profoundly impact quality of life and overall health care burden. Demetrios Vavvas and colleagues at the Mass Eye and Ear Infirmary (MEEI) have revealed a critical redundant role of mediators of both apoptosis and necrosisin cell death in the neuroretina and optic… More